38.60
+1.27(+3.40%)
Currency In USD
| Previous Close | 37.33 |
| Open | 38 |
| Day High | 39.07 |
| Day Low | 37 |
| 52-Week High | 45 |
| 52-Week Low | 7.65 |
| Volume | 134,675 |
| Average Volume | 54,235 |
| Market Cap | 819M |
| PE | -1.7 |
| EPS | -22.75 |
| Moving Average 50 Days | 22.08 |
| Moving Average 200 Days | 13.64 |
| Change | 1.27 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $114.27 as of December 25, 2025 at a share price of $38.6. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $694.24 as of December 25, 2025 at a share price of $38.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 07, 2025 9:30 PM GMT
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
GlobeNewswire Inc.
Nov 10, 2025 12:30 PM GMT
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 c
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two ab